Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Free Cash Flow (2018 - 2025)

Neurogene's Free Cash Flow history spans 6 years, with the latest figure at -$17.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow changed 0.2% year-over-year to -$17.6 million; the TTM value through Dec 2025 reached -$77.3 million, down 8.21%, while the annual FY2025 figure was -$77.3 million, 8.21% down from the prior year.
  • Free Cash Flow reached -$17.6 million in Q4 2025 per NGNE's latest filing, up from -$19.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$9.4 million in Q2 2023 to a low of -$21.8 million in Q1 2024.
  • Average Free Cash Flow over 3 years is -$16.7 million, with a median of -$17.4 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: tumbled 66.67% in 2024, then rose 1.2% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$17.2 million in 2023, then dropped by 2.27% to -$17.6 million in 2024, then increased by 0.2% to -$17.6 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Free Cash Flow are -$17.6 million (Q4 2025), -$19.3 million (Q3 2025), and -$18.8 million (Q2 2025).